Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin Pruritus
Primary Purpose
Skin Pruritus
Status
Completed
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
PAC-14028
Vehicle
Sponsored by
About this trial
This is an interventional treatment trial for Skin Pruritus
Eligibility Criteria
Inclusion Criteria:
- Male and female patients at the age of 20 to 65 years old (both inclusive)
- Pruritus test ≥ 5cm (10cm Visual Analogue Scale [VAS]) at baseline
- Eczema or dry skin on the study drug application site
- Women of childbearing potential should have a negative urine pregnancy test at screening and agree to employ an effective method of birth control (surgical sterilization or oral contraceptives, barrier method with spermicides, intrauterine device, etc.) during the study period.
- Voluntarily signed written informed consent forms for study participation.
Exclusion Criteria:
- Pruritus due to other medical (liver disease, renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease.
- Chronic skin diseases such as malignant tumor or chronic urticaria, among skin diseases.
- Simple pruritus caused by allergic substances such as scabies or insect bites.
- Presence of symptoms of generalized infection at the time of study participation.
- Previous local treatment or antibiotics administration for pruritus within 7 days prior to study participation.
- Previous use of oral steroids within 1 month and local steroids within 2 weeks prior to study participation.
- History of physical treatment for pruritus, including phototherapy, within 1 month prior to study participation.
- Patients who are treated with prohibited concomitant drugs or considered to inevitably require treatment with prohibited concomitant drugs during the study period.
- Renal function impairment with creatinine level
- Hepatic function impairment with aspartate aminotransferase (AST)/ alanine aminotransferase (ALT)
- Pregnant and lactating women
- Participation in another clinical study within 1 month prior to screening.
- Patients considered ineligible for study participation by the principal investigator or sub-investigator for other reasons; pruritus due to other medical (liver disease, renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease.
Sites / Locations
- Kyu-Han Kim
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
PAC-14028 cream 0.3%
PAC-14028 cream 1.0%
Vehicle
Arm Description
PAC-14028 cream 0.3%, twice daily for 28 days
PAC-14028 cream 1.0%, twice daily for 28days
Vehicle, twice daily for 28days
Outcomes
Primary Outcome Measures
Change in Visual Analog Scale (VAS)
Patient reported outcome of pruritis measurement on a change in visual analog scale
Secondary Outcome Measures
Treatment success rate
Change in specified symptom sum score (SRRC) Index
Change in transepidermal water loss
Change in skin hydration
Full Information
NCT ID
NCT02052531
First Posted
January 31, 2014
Last Updated
September 11, 2015
Sponsor
Amorepacific Corporation
1. Study Identification
Unique Protocol Identification Number
NCT02052531
Brief Title
Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin Pruritus
Official Title
A Phase II, Single Center, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of PAC-14028 Cream in Dermal Pruritus
Study Type
Interventional
2. Study Status
Record Verification Date
September 2015
Overall Recruitment Status
Completed
Study Start Date
January 2013 (undefined)
Primary Completion Date
June 2013 (Actual)
Study Completion Date
July 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Amorepacific Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The objective of this study was to find a clinically appropriate dose of PAC-14028 cream by comparatively evaluating the efficacy and safety of PAC-14028 cream of Amorepacific Corporation in patients with dermal pruritus.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Skin Pruritus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
74 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PAC-14028 cream 0.3%
Arm Type
Experimental
Arm Description
PAC-14028 cream 0.3%, twice daily for 28 days
Arm Title
PAC-14028 cream 1.0%
Arm Type
Experimental
Arm Description
PAC-14028 cream 1.0%, twice daily for 28days
Arm Title
Vehicle
Arm Type
Placebo Comparator
Arm Description
Vehicle, twice daily for 28days
Intervention Type
Drug
Intervention Name(s)
PAC-14028
Other Intervention Name(s)
PAC-14028 Cream 0.3%, PAC-14028 Cream 1.0%
Intervention Description
Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
Intervention Type
Other
Intervention Name(s)
Vehicle
Other Intervention Name(s)
Vehicle of PAC-14028 Cream
Intervention Description
Participants received topical Vehicle twice daily for 4 weeks
Primary Outcome Measure Information:
Title
Change in Visual Analog Scale (VAS)
Description
Patient reported outcome of pruritis measurement on a change in visual analog scale
Time Frame
Baseline through Study Day 28
Secondary Outcome Measure Information:
Title
Treatment success rate
Time Frame
Baseline through Study Day 28
Title
Change in specified symptom sum score (SRRC) Index
Time Frame
Baseline through Study Day 28
Title
Change in transepidermal water loss
Time Frame
Baseline through Study Day 28
Title
Change in skin hydration
Time Frame
Baseline through Study Day 28
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female patients at the age of 20 to 65 years old (both inclusive)
Pruritus test ≥ 5cm (10cm Visual Analogue Scale [VAS]) at baseline
Eczema or dry skin on the study drug application site
Women of childbearing potential should have a negative urine pregnancy test at screening and agree to employ an effective method of birth control (surgical sterilization or oral contraceptives, barrier method with spermicides, intrauterine device, etc.) during the study period.
Voluntarily signed written informed consent forms for study participation.
Exclusion Criteria:
Pruritus due to other medical (liver disease, renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease.
Chronic skin diseases such as malignant tumor or chronic urticaria, among skin diseases.
Simple pruritus caused by allergic substances such as scabies or insect bites.
Presence of symptoms of generalized infection at the time of study participation.
Previous local treatment or antibiotics administration for pruritus within 7 days prior to study participation.
Previous use of oral steroids within 1 month and local steroids within 2 weeks prior to study participation.
History of physical treatment for pruritus, including phototherapy, within 1 month prior to study participation.
Patients who are treated with prohibited concomitant drugs or considered to inevitably require treatment with prohibited concomitant drugs during the study period.
Renal function impairment with creatinine level
Hepatic function impairment with aspartate aminotransferase (AST)/ alanine aminotransferase (ALT)
Pregnant and lactating women
Participation in another clinical study within 1 month prior to screening.
Patients considered ineligible for study participation by the principal investigator or sub-investigator for other reasons; pruritus due to other medical (liver disease, renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kyu-Han Kim, MD,Ph.D
Organizational Affiliation
Department of Dermatology, Seoul National University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kyu-Han Kim
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin Pruritus
We'll reach out to this number within 24 hrs